Minapharm Pharmaceuticals (CAI:MIPH) Cash Flow for Dividends: E£-60 Mil (TTM As of Dec. 2025)


CAI:MIPH Minapharm Pharmaceuticals CAI:MIPH
41 GF Score
Price E£698.08
GF Value E£362.31
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Minapharm Pharmaceuticals Cash Flow for Dividends?

Minapharm Pharmaceuticals CAI:MIPH -0.27% 41 Cash Flow for Dividends is E£-60 Mil as of Dec. 2025. GuruFocus rates CAI:MIPH with a GF Score™ of 41/100 and a GF Value™ of E£362.31 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Minapharm Pharmaceuticals's cash flow for dividends for the three months ended in Dec. 2025 was E£-16 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2025 was E£-60 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Minapharm Pharmaceuticals's quarterly payment of dividends increased from Jun. 2025 (E£-2 Mil) to Sep. 2025 (E£-42 Mil) but then declined from Sep. 2025 (E£-42 Mil) to Dec. 2025 (E£-16 Mil).

Minapharm Pharmaceuticals's annual payment of dividends declined from Dec. 2023 (E£-54 Mil) to Dec. 2024 (E£-40 Mil) but then increased from Dec. 2024 (E£-40 Mil) to Dec. 2025 (E£-60 Mil).

Minapharm Pharmaceuticals Cash Flow for Dividends Related Terms

Minapharm Pharmaceuticals Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Minapharm Pharmaceuticals's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minapharm Pharmaceuticals Cash Flow for Dividends Chart

Minapharm Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
-49.80 -57.79 -53.87 -40.16 -60.31

Minapharm Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.02 -1.95 -41.93 -16.41
CAI:MIPH
41GF Score
Minapharm Pharmaceuticals CAI:MIPH
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minapharm Pharmaceuticals Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was E£-60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of E£-60 Mil mean?
Minapharm Pharmaceuticals (CAI:MIPH) has a Cash Flow for Dividends of E£-60 Mil as of Dec. 2025. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Minapharm Pharmaceuticals and its competitors.
Is Minapharm Pharmaceuticals' Cash Flow for Dividends too high?
Minapharm Pharmaceuticals' current Cash Flow for Dividends is E£-60 Mil. Overall, Minapharm Pharmaceuticals has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' Cash Flow for Dividends compare to ZTS and UTHR?
Minapharm Pharmaceuticals' Cash Flow for Dividends of E£-60 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Drug Manufacturers company?
A good Cash Flow for Dividends depends on the Drug Manufacturers industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Minapharm Pharmaceuticals and its competitors. Minapharm Pharmaceuticals's current Cash Flow for Dividends is E£-60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£362.31, compared to a current price of E£698.08 — trading 92.7% above its estimated fair value. The current Cash Flow for Dividends is E£-60 Mil. Minapharm Pharmaceuticals' overall GF Score™ is 41/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current Cash Flow for Dividends is E£-60 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?

Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued. The current stock price of E£698.08 is trading 92.7% above its estimated GF Value™ of E£362.31. GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CAI:MIPH:

  • Cash Flow for Dividends: E£-60 Mil
  • GF Value™: E£362.31 vs. price of E£698.08 (92.7% above fair value)
  • GF Score™: 41/100 with 10 warning signs

No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Minapharm Pharmaceuticals Business Description

Address El-Bardissi Street, 2T Takseem Asmaa Fahmy Street, Heliopolis, Cairo, EGY
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
41GF Score

Get the complete analysis for CAI:MIPH

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£698.08
Price
E£362.31
GF Value